Papillary Thyroid Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Papillary Thyroid Cancer - Pipeline Review, H1 2016', provides an overview of the Papillary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer - The report reviews pipeline therapeutics for Papillary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Papillary Thyroid Cancer therapeutics and enlists all their major and minor projects - The report assesses Papillary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Papillary Thyroid Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Papillary Thyroid Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Papillary Thyroid Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Papillary Thyroid Cancer - Overview 8 Pipeline Products for Papillary Thyroid Cancer - Comparative Analysis 9 Papillary Thyroid Cancer - Therapeutics under Development by Companies 10 Papillary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11 Papillary Thyroid Cancer - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Papillary Thyroid Cancer - Products under Development by Companies 15 Papillary Thyroid Cancer - Products under Investigation by Universities/Institutes 16 Papillary Thyroid Cancer - Companies Involved in Therapeutics Development 17 Exelixis, Inc. 17 Genzyme Corporation 18 Ignyta, Inc. 19 Novartis AG 20 Pfizer Inc. 21 Plexxikon Inc. 22 Vaccinex, Inc. 23 Papillary Thyroid Cancer - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 cabozantinib s-malate - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CLM-3 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 dabrafenib mesylate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 entrectinib - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 everolimus - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 pasireotide - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 PLX-7486 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 PLX-8394 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 sunitinib malate - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 vandetanib - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 VX-15 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Papillary Thyroid Cancer - Recent Pipeline Updates 71 Papillary Thyroid Cancer - Dormant Projects 102 Papillary Thyroid Cancer - Discontinued Products 103 Papillary Thyroid Cancer - Product Development Milestones 104 Featured News & Press Releases 104 Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 104 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 105 Disclaimer 106
List of Tables
Number of Products under Development for Papillary Thyroid Cancer, H1 2016 8 Number of Products under Development for Papillary Thyroid Cancer - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Papillary Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2016 17 Papillary Thyroid Cancer - Pipeline by Genzyme Corporation, H1 2016 18 Papillary Thyroid Cancer - Pipeline by Ignyta, Inc., H1 2016 19 Papillary Thyroid Cancer - Pipeline by Novartis AG, H1 2016 20 Papillary Thyroid Cancer - Pipeline by Pfizer Inc., H1 2016 21 Papillary Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2016 22 Papillary Thyroid Cancer - Pipeline by Vaccinex, Inc., H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 29 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Papillary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016 71 Papillary Thyroid Cancer - Dormant Projects, H1 2016 102 Papillary Thyroid Cancer - Discontinued Products, H1 2016 103
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.